Curon Medical Stretta System
This article was originally published in The Gray Sheet
Executive Summary
Device for treatment of gastroesophageal reflux disease (GERD) receives FDA market go-ahead. The procedure applies controlled radiofrequency energy through a flexible catheter to the lower esophageal sphincter to improve the barrier function of the valve and stop reflux. Bard's endoscopic suturing device for GERD received 510(k) clearance on March 20 (1"The Gray Sheet" April 10, p. 11)
You may also be interested in...
Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.
Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.
Bard Views GI, AAA Devices And Brachytherapy Seeds As Key Growth Drivers
Bard is hopeful that the Health Care Financing Administration will deem the firm's endoscopic suturing system for gastroesophageal reflux disease eligible for supplementary reimbursement under the agency's outpatient prospective payment system.